Deng et al. (173) found that treatment with Mdivi-1 (20 mg/kg/day) significantly reduced angiotensin II-induced hypertension, arterial remodeling, and cardiac hypertrophy by a mechanism that may be related to preventing phenotypic transformation of VSMCs. The gene discussed is AGT; the disease is cardiac hypertrophy.